National Vaccine
Information Center

Your Health. Your Family. Your Choice.

MedAlerts Home
Search Results

From the 9/10/2021 release of VAERS data:

This is VAERS ID 1416259

Case Details

VAERS ID: 1416259 (history)  
Form: Version 2.0  
Age: 45.0  
Sex: Female  
Location: Foreign  
   Days after vaccination:0
Submitted: 0000-00-00
Entered: 2021-06-21
Vaccin­ation / Manu­facturer Lot / Dose Site / Route

Administered by: Other       Purchased by: ?
Symptoms: Pharyngeal stenosis, Rhinorrhoea
SMQs:, Oropharyngeal conditions (excl neoplasms, infections and allergies) (narrow)

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? Yes
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications:
Current Illness:
Preexisting Conditions:
Diagnostic Lab Data:
CDC Split Type: JPPFIZER INC2021666095

Write-up: Pharyngeal stenosis; Nasal discharge; This is a spontaneous report received from a contactable other health care professional via Pfizer sales representative. The patient was a 45-year-old female. It was unknown whether the patient had other medical history. On 04Jun2021 (the day of vaccination), the patient received the single dose of BNT162B2 (COMIRNATY, Solution for injection, Lot number unknown) for COVID-19 immunization. On 04Jun2021, the patient experienced Pharyngeal stenosis and nasal discharge. The outcome of the event was recovered on 04Jun2021. The details of the reaction were reported as follow: on 04Jun2021, after vaccination with medical staff, there was a feeling of pharyngeal stenosis and nasal discharge. Both symptoms recovered during the day. Reporter considered that the event was non-serious and the causality between the BNT162B2 and event was probably related. Information on the lot/batch number has been requested.; Sender''s Comments: Based on the information currently available, a causal association between the reported event pharyngeal stenosis and BNT162B2 cannot be fully excluded. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to RAs, Ethics Committees, and investigators, as appropriate.

New Search

Link To This Search Result:

Copyright © 2021 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166